Granulocyte surface proteins

Granulocyte surface proteins refer to a diverse group of proteins expressed on the plasma membrane of granulocytes, including neutrophils, eosinophils, and basophils [1, 5]. This category encompasses various functional molecules such as adhesion molecules (e.g., CD11b/CD18), Fc receptors (e.g., CD16, CD32, CD64), and lineage-specific antigens (e.g., CD66b, CD15, CD177) [2, 5]. These proteins are essential for the innate immune response, mediating processes such as cell activation, adhesion to vascular endothelium, chemotaxis toward inflammatory sites, and phagocytosis of pathogens [4, 5]. In clinical pharmacology, these proteins are primarily targeted by radiolabeled monoclonal antibodies, such as Besilesomab and Sulesomab, which bind to CD66 antigens to image infections and inflammatory foci [1, 2]. Additionally, receptors like the Granulocyte colony-stimulating factor receptor (G-CSFR) are targeted by drugs like Filgrastim to stimulate neutrophil production [5]. They also serve as vital biomarkers for immunophenotyping and are involved in the pathogenesis of conditions like Transfusion-Related Acute Lung Injury (TRALI) [4]. While not a single therapeutic target, the detection and modulation of these surface proteins are central to the diagnosis and management of inflammatory and hematologic disorders [1, 3].

Other names

Granulocyte antigensNeutrophil surface proteinsGranulocyte-specific antigensHuman Neutrophil Antigens (HNA)Granulocyte surface markers

Binding to specific surface antigens (e.g., CD66b, CD66c, CD15) on granulocytes to facilitate diagnostic imaging of inflammatory sites, or activation of specific receptors (e.g., G-CSFR, GM-CSFR) to stimulate granulocyte production and function.